WAY-200070
WAY-200070-3 · Br-ERb-041 · 7-bromo-2-(4-hydroxyphenyl)-1 · 3-benzoxazol-5-ol
Last updated
At a glance
Overview
What WAY-200070 Actually Is#
WAY-200070 is a small-molecule selective estrogen receptor β agonist — roughly 68-fold selective for ERβ over ERα (IC₅₀ 2.3 nM vs 155 nM), originally synthesized at Wyeth as a research probe to dissect ERβ-specific biology away from the classical proliferative ERα signal. It never advanced into clinical development and exists today as a reagent-grade chemistry tool, most commonly catalogued through Sigma-Aldrich and equivalent suppliers.
The reason it shows up at all in physique-optimization and longevity reading lists is the shape of ERβ activation: anti-proliferative in prostate tissue, insulin-sensitizing in pancreatic β-cells, neurochemically active on dopamine and serotonin, and notably without the uterine, mammary, and water-retention signature that defines ERα stimulation. In the Alonso-Magdalena diabetes work, two weeks of 10 mg/kg restored first-phase insulin secretion and expanded β-cell mass in mice; in Hughes 2008, 30 mg/kg produced sustained striatal dopamine elevation and antidepressant-like behavioral readouts that disappeared in ERβ-knockout animals.
"WAY-200070 is a potent and selective ERβ agonist that, at doses of 30 mg/kg, produced a rapid and sustained increase in striatal dopamine and a transient increase in serotonin, accompanied by behavioral changes resembling antidepressant and anxiolytic effects." — Hughes et al., Neuropharmacology (2008)
That said, this compound sits in a different category than the peptides and SARMs typically profiled here. There is no human PK data, no toxicology package, and no community dosing log of meaningful size — all published numbers are rodent mg/kg figures, and translation to a human-equivalent dose is speculative. The sections below cover the documented ERβ mechanism, preclinical dose ranges across CNS and metabolic models, theoretical stack logic against AAS-driven ERα overstimulation, side-effect unknowns, and the sourcing reality that separates WAY-200070 from mainstream research peptides.
How WAY-200070 works
ERβ-Selective Receptor Binding#
WAY-200070 is a benzoxazole-class small molecule that binds estrogen receptor β (ERβ) with roughly 68-fold selectivity over ERα (IC₅₀ 2.3 nM at ERβ vs 155 nM at ERα). That selectivity is the entire pharmacologic point of the molecule: ERα drives the classic estrogenic signature physique-focused users want to avoid — mammary proliferation, uterine growth, water retention, gynecomastia risk in males, thromboembolic load — while ERβ acts as a brake on ERα- and AR-driven proliferation in tissues like prostate, colon, and vascular endothelium.
Receptor engagement is fast. Cytosolic ERβ translocates to the nucleus within 15 minutes of subcutaneous administration in rodents, with c-fos induction following at ~4 hours and abolished in ERβ-knockout animals — confirming the response is genuinely β-mediated rather than α-bleed-through at the doses tested.
"WAY-200070 exhibits approximately 68-fold selectivity for estrogen receptor β over α, with an IC50 of 2.3 nM for ERβ and 155 nM for ERα." — Sigma-Aldrich, Product Monograph (2024)
The practical implication: at clean doses, the molecule recruits the anti-proliferative, insulin-sensitizing, neuro-modulatory arm of estrogen signalling without the feminizing arm. At supratherapeutic exposure, selectivity collapses and ERα is recruited — which is where the gyno/water/clot risks re-enter the picture.
Monoaminergic Modulation in the CNS#
ERβ activation in the brain drives dopamine and serotonin output. In wild-type mice given 30 mg/kg s.c., striatal dopamine rose roughly 50% in a sustained fashion, with a transient ~100% rise in serotonin. ERβ-knockout controls showed neither response and exhibited reduced frontal-cortex 5-HTP, implicating ERβ in tryptophan-hydroxylase tone.
"WAY-200070 is a potent and selective ERβ agonist that, at doses of 30 mg/kg, produced a rapid and sustained increase in striatal dopamine and a transient increase in serotonin, accompanied by behavioral changes resembling antidepressant and anxiolytic effects." — Hughes ZA et al., Neuropharmacology (2008)
Behavioral readouts followed: reduced immobility in tail-suspension, increased punished crossings in the four-plate test, attenuated stress-induced hyperthermia. The relevance for physique-focused users is conceptual rather than translational — ERβ tone overlaps the same mood/anxiety/cortisol axis that gets stressed on heavy AAS cycles — but no human data exist to anchor a dose.
Pancreatic β-Cell Trophism and Insulin Sensitization#
The cleanest preclinical signal sits in glucose handling. WAY-200070 closes K-ATP channels in mouse β-cells at picomolar concentrations, enhances glucose-stimulated calcium influx, and potentiates insulin secretion in both murine and human islets. Two weeks of 10 mg/kg i.p. once-daily dosing in C57BL/6 mice expanded β-cell mass and improved both glucose tolerance and peripheral insulin sensitivity; in streptozotocin-nicotinamide and db/db diabetic models, the same protocol restored first-phase insulin release and regenerated β-cell mass.
"Chronic treatment with WAY-200070 restored first-phase insulin secretion and increased β-cell mass in C57BL/6 mice, with significant improvement in glucose tolerance and insulin sensitivity." — Alonso-Magdalena P et al., Diabetes (2013)
This is the mechanism that puts WAY-200070 in the same conceptual bucket as low-dose tadalafil, berberine, and metformin for managing on-cycle insulin resistance — ERβ delivers insulin-sensitizing benefit without the ERα-driven mammary/uterine proliferation that would make estrogenic ligands unusable in that role. The catch: this has never been replicated in humans.
Hypothalamic GnRH/Galanin Axis#
ERβ is densely expressed in GnRH-immunoreactive neurons of the hypothalamus, and WAY-200070 induces robust galanin co-expression within those neurons in ovariectomized female rats.
"Selective ERβ ligands, including WAY-200070, induce robust galanin expression in GnRH-immunoreactive neurons of the female rat hypothalamus." — Merchenthaler I et al., Endocrinology (2005)
Galanin co-release modulates GnRH pulsatility, which feeds forward to LH/FSH output. The implication is that ERβ tone is not HPTA-neutral — it modulates the gonadotropin axis through a distinct lever from the classic ERα/AR feedback loop. For anyone running this alongside an AAS protocol or PCT, the axis effects are uncharacterized in humans and worth flagging in bloodwork (LH, FSH, prolactin, ultrasensitive E2).
SERM Cross-Talk and Proliferation Signalling#
WAY-200070 on its own does not inhibit growth of ER+ MCF-7 or T-47D breast cancer cells. Combined with tamoxifen, however, it potentiates tamoxifen's growth-inhibitory effect on both lines (Lattrich 2013). The mechanism appears to be ERβ-driven antagonism of ERα-mediated proliferative signalling — ERβ heterodimerizing with ERα blunts the α-driven transcriptional program.
This matters for two practical reasons: (1) it confirms the conceptual model that ERβ tone counter-balances ERα drive, which is the rationale for any physique-context use; (2) it flags a real drug interaction with tamoxifen and, by extension, with raloxifene and other SERMs commonly used as PCT or gyno-management ancillaries. Co-administration is not a clean additive — the pharmacology is genuinely modified.
Behavioral and Dominance Effects#
Acute ERβ activation increases non-attack dominance behaviors — pushing-down, aggressive grooming — in both intact male and female CD-1 mice, without raising attack frequency (Clipperton-Allen 2010). The signal is consistent with the dopaminergic activation profile from Hughes 2008 and points to ERβ as a modulator of confidence/assertiveness-type behaviors distinct from androgen-driven aggression. Translationally speculative, but mechanistically coherent with the broader monoaminergic profile.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 3–10 mg/kg (rodent only) | Once daily | Documented entry-level range |
| Mid | 10–20 mg/kg (rodent only) | Once daily | Most commonly studied range |
| High | 20–30 mg/kg (rodent only) | Once daily | All published dosing is rodent-derived. CNS endpoints active at 30 mg/kg s.c. once daily (Hughes 2008); metabolic endpoints active at 10 mg/kg i.p. once daily for 14 days (Alonso-Magdalena 2013). No validated human-equivalent dose exists. |
Cycle length & outcomes
Documented cycle
2–4 weeks
Plateau after
4 wks
Cycle Notes#
WAY-200070 has no validated human cycle. Every published protocol is rodent-based, all numbers below are translated from preclinical work in mg/kg, and there is no PK or toxicology package in any species beyond two-week metabolic dosing. The "cycle length" question is genuinely open — what follows is a synthesis of the documented preclinical paradigms, framed for research use.
WAY-200070 Protocol Length by Research Endpoint#
| Research Endpoint | Documented Duration | Documented Dose (rodent) | Frequency |
|---|---|---|---|
| CNS / mood-axis pharmacology | 1–14 days | 30 mg/kg s.c. | Once daily |
| β-cell function / glucose tolerance | 14 days | 10 mg/kg i.p. | Once daily |
| Hypothalamic galanin / GnRH-axis | 2–4 days | 5–10 mg/kg s.c. | Once daily |
| Dominance / behavioral acute | Single dose | 1–10 mg/kg s.c. | Acute |
| Breast-cancer cell co-incubation | 6 days (in vitro) | 1 nM – 100 nM | Continuous exposure |
The longest documented in-vivo protocol is the 14-day Alonso-Magdalena β-cell study at 10 mg/kg i.p. once daily.
"Chronic treatment with WAY-200070 restored first-phase insulin secretion and increased β-cell mass in C57BL/6 mice, with significant improvement in glucose tolerance and insulin sensitivity." — Alonso-Magdalena et al., Diabetes (2013)
Nothing longer has been published. Anyone extrapolating beyond a 4-week research protocol is operating without preclinical safety cover.
Loading and Tapering#
There is no loading phase in any published WAY-200070 work. The CNS protocol in Hughes 2008 generated measurable striatal dopamine elevation and behavioral effects from the first 30 mg/kg s.c. dose, with receptor translocation at 15 minutes and c-fos induction by 4 hours. The metabolic protocol in Alonso-Magdalena 2013 used a flat 10 mg/kg daily dose for two weeks without titration.
"WAY-200070 is a potent and selective ERβ agonist that, at doses of 30 mg/kg, produced a rapid and sustained increase in striatal dopamine and a transient increase in serotonin, accompanied by behavioral changes resembling antidepressant and anxiolytic effects." — Hughes et al., Neuropharmacology (2008)
Tapering is similarly undocumented. Because ERβ activation modulates HPA-axis tone, GnRH/galanin signaling, and monoaminergic firing, abrupt discontinuation after a multi-week protocol carries theoretical rebound risk on mood, libido, and menstrual cycling — none of which has been measured. A conservative wind-down (50% dose for 3–5 days) is a defensible default in research planning, but it is not validated.
Onset and Functional Duration#
Preclinical timing is reasonably well characterized:
- Receptor engagement: 15 minutes post-dose (cytosolic-to-nuclear ERβ translocation)
- Transcriptional readout: ~4 hours (c-fos)
- Behavioral / neurochemical peak: 90–240 minutes after s.c. administration
- Functional duration: ≥24 hours at 10 mg/kg in mice, inferred from once-daily dosing producing cumulative β-cell and glycemic effects
- Metabolic-endpoint detection: measurable by day 7, full effect by day 14 in the C57BL/6 model
For CNS endpoints the molecule behaves like a short-acting agent with rapid on/off pharmacodynamics. For tissue-trophic endpoints (β-cell mass) it requires the full 2-week window to express its effect.
Bloodwork Cadence#
No clinical monitoring framework exists. For any research protocol approaching the 2–4 week window, the panels that would surface mechanism-relevant changes are:
- Baseline (within 2 weeks of initiation): CBC, CMP (ALT/AST/lipids/glucose), fasting insulin, HOMA-IR, ultrasensitive estradiol (LC-MS), total/free testosterone, SHBG, prolactin, PSA (males), TSH
- Mid-protocol (day 10–14): fasting insulin, glucose, estradiol, prolactin
- End-of-protocol: full repeat of baseline panel
- Post-protocol (4 weeks off): estradiol, LH/FSH, fasting insulin — to capture any HPG- or insulin-axis rebound
The estradiol assay should be LC-MS, not immunoassay — at supratherapeutic exposures, ERα bleed-through is the relevant safety question, and ERβ agonism itself can shift downstream estrogenic readouts without changing measured E2.
Cycle-Length Logic#
The conservative ceiling on any research protocol is 4 weeks, derived directly from the longest published in-vivo study doubled to allow a tapered exit. The case for staying ≤4 weeks:
- No chronic toxicology data in any species.
- ERβ modulates GnRH-neuron output (Merchenthaler 2005) — sustained activation has unmapped consequences for the HPG axis in either sex.
- ERα recruitment increases nonlinearly with exposure. At 68-fold β-selectivity, the safety margin against ERα-driven proliferation, water retention, and thromboembolic risk depends entirely on staying within the documented dose range — which itself is rodent-derived.
- Tamoxifen interaction is documented in vitro (Lattrich 2013), making this a non-trivial compound to combine with any SERM-based ancillary stack.
"WAY-200070 alone did not inhibit proliferation of MCF-7 or T-47D cells, but when combined with tamoxifen, its presence significantly potentiated the growth-inhibitory effect of tamoxifen in both cell lines." — Lattrich et al., Arch Gynecol Obstet (2014)
A 2-week research window matches the cleanest published efficacy signal (β-cell trophism). A 4-week window allows wash-in and a tapered exit. Anything beyond that exits the preclinical envelope entirely.
Risks & mistakes
Common (most users)#
There is no human safety dataset for WAY-200070. The molecule has never progressed past rodent pharmacology, and no chronic-dosing toxicology package exists in any species. What follows is mechanistically inferred from preclinical work — not a documented adverse-event log.
In the published rodent studies that ran 14 days at 10–30 mg/kg, the following were not reported as problems, which is informative but does not equal a clean profile:
- Acute behavioral changes — Hughes 2008 documented increases in non-aggressive dominance behavior and antidepressant/anxiolytic-like effects at 30 mg/kg s.c. Behavioral shifts are an expected pharmacodynamic readout, not a side effect per se, but anyone modeling CNS endpoints should expect altered baseline behavior on-compound.
"WAY-200070 is a potent and selective ERβ agonist that, at doses of 30 mg/kg, produced a rapid and sustained increase in striatal dopamine and a transient increase in serotonin, accompanied by behavioral changes resembling antidepressant and anxiolytic effects." — Hughes 2008
- Vehicle-related injection-site reactions — published protocols use sesame oil (s.c.) or DMSO/saline (i.p.). Vehicle, not WAY-200070, drives most local effects in rodent work.
Uncommon (dose-dependent or individual)#
These are the categories where ERβ pharmacology — and any inferred off-target ERα activity at supratherapeutic exposure — would be expected to show up. None has been formally characterized.
- ERα bleed-through at high exposure — 68-fold β-over-α selectivity (IC₅₀ 2.3 nM ERβ vs 155 nM ERα) is meaningful but not absolute. At supratherapeutic concentrations, classical ERα effects (water retention, gynecomastia signal in males, mammary/endometrial proliferation, thromboembolic risk) become plausible. Selectivity is a margin, not a guarantee.
"WAY-200070 exhibits approximately 68-fold selectivity for estrogen receptor β over α, with an IC50 of 2.3 nM for ERβ and 155 nM for ERα." — Sigma-Aldrich monograph 2024
- Glycemic shift — chronic ERβ activation expanded β-cell mass and potentiated insulin secretion in mice (Alonso-Magdalena 2013). In a metabolically healthy subject, the theoretical concern is enhanced postprandial insulin response and downstream hypoglycemic episodes, particularly when stacked with other insulin-sensitizing agents (metformin, berberine, GLP-1 analogs) or exogenous insulin.
"Chronic treatment with WAY-200070 restored first-phase insulin secretion and increased β-cell mass in C57BL/6 mice, with significant improvement in glucose tolerance and insulin sensitivity." — Alonso-Magdalena 2013
- HPG-axis perturbation — ERβ agonism induced galanin co-expression in GnRH neurons of female rats (Merchenthaler 2005). The translational implication for menstrual regularity, LH pulsatility, and recovery of endogenous testosterone post-AAS is unknown and not favorable to assume away.
- Mood and sleep architecture changes — combined dopaminergic and serotonergic activation in the Hughes 2008 model is interesting on paper but unpredictable in subjects already on SSRIs, SNRIs, bupropion, or MAOIs. Bloodwork doesn't catch this; subjective tracking does.
- Lipid panel drift — not measured in the rodent studies. ERβ tone interacts with hepatic lipid handling distinctly from ERα. Baseline and 4-week lipid panels are warranted in any research protocol.
Bloodwork worth running at baseline and at 4 weeks: ALT/AST, fasting insulin and glucose, full lipid panel, ultrasensitive estradiol (LC-MS), prolactin, PSA in male subjects, and full CBC. Discontinuation is warranted on any clear directional drift outside reference range.
Rare but serious#
No incidence data exist. The following are mechanism-derived flags, not documented cases:
- Thromboembolic events — any estrogenic ligand carries a theoretical clot risk via hepatic clotting-factor synthesis. ERβ activation alone has not been linked to this in preclinical work, but ERα bleed-through at supratherapeutic exposure would re-introduce the concern. Unilateral leg swelling, calf pain, chest pain, dyspnea, or sudden neurological deficit warrants immediate discontinuation and emergency evaluation.
- Severe hypoglycemia — if β-cell trophic effects translate to humans and the molecule is stacked with insulin, sulfonylureas, or aggressive fasting, hypoglycemic events are mechanistically foreseeable. Sweating, tremor, confusion, loss of consciousness — discontinue and address with carbohydrate.
- Endometrial or mammary proliferation in female subjects — unmeasured. Any abnormal uterine bleeding, breast lump, or unexplained galactorrhea is a discontinuation event pending workup.
- Unmasking of occult ER-positive malignancy — the Lattrich 2013 in-vitro work showed WAY-200070 did not inhibit MCF-7 or T-47D proliferation as monotherapy. The behavior of the molecule on undiagnosed ER+ disease is unknown.
"WAY-200070 alone did not inhibit proliferation of MCF-7 or T-47D cells, but when combined with tamoxifen, its presence significantly potentiated the growth-inhibitory effect of tamoxifen in both cell lines." — Lattrich 2013
Hard contraindications#
These lines do not get crossed. State them plainly:
- Pregnancy or pregnancy potential. An uncharacterized estrogenic ligand with documented effects on hypothalamic GnRH circuitry cannot be used in any subject who is pregnant, may become pregnant, or is lactating. Teratogenic and developmental endpoints have never been assessed.
- Personal or family history of ER-positive breast cancer. WAY-200070 does not inhibit ER+ proliferation as monotherapy (Lattrich 2013) and modifies the activity of SERMs in vitro — not a compound to introduce in this population.
- Active or prior thromboembolic disease — DVT, PE, stroke, MI history. Estrogenic ligands belong nowhere near this profile.
- Concurrent tamoxifen or aromatase-inhibitor therapy. In-vitro potentiation of tamoxifen's anti-proliferative effect (Lattrich 2013) means the molecule modifies the pharmacology of standard SERM/AI regimens in ways neither characterized nor predictable. This includes anyone running tamoxifen or an AI as on-cycle E2 control or as PCT.
- Undiagnosed abnormal uterine bleeding — workup before any estrogenic ligand.
- Active hepatic disease — phenol/benzoxazole metabolism is hepatic; no human hepatotoxicity data exist.
- Sourcing from chemical-reagent vendors for parenteral research use — reagent CoAs cover chemical purity, not bioburden or endotoxin. Parenteral preparation of reagent-grade WAY-200070 is not equivalent to a sterile, endotoxin-tested formulation, and no such formulation exists.
Gender-specific considerations and ancillaries#
Female subjects. ERβ-selective agonism induces galanin within GnRH-immunoreactive neurons of the female rat hypothalamus (Merchenthaler 2005), implicating direct modulation of gonadotropin output. Menstrual cycling, fertility, and any pregnancy potential are absolute contraindications. The Clipperton-Allen 2010 work additionally showed acute behavioral effects in both intact and gonadectomized females.
"Selective ERβ ligands, including WAY-200070, induce robust galanin expression in GnRH-immunoreactive neurons of the female rat hypothalamus." — Merchenthaler 2005
Male subjects. No documented suppression of the HPG axis from ERβ-selective agonism in published rodent work, but the molecule has never been characterized for endogenous testosterone, LH, or FSH effects in any species at chronic exposure. Recovery dynamics post-discontinuation are unknown.
PCT considerations. WAY-200070 is not androgenic and does not suppress HPTA in any documented protocol, so a dedicated PCT for the molecule itself is not indicated. However, the in-vitro tamoxifen-potentiation finding (Lattrich 2013) is a direct flag against co-administration with the SERMs that anchor most AAS PCT protocols — tamoxifen, clomiphene, raloxifene, enclomiphene. WAY-200070 has no place inside a PCT window, and stacking it with an AAS cycle's on-cycle AI (anastrozole, exemestane, letrozole) introduces an uncharacterized pharmacologic interaction at the ER. The clean answer: WAY-200070 stays separated from any AAS cycle and from any SERM/AI ancillary protocol until human characterization exists.
FAQ — WAY-200070
Research & citations
6 studies cited on this page.
Conclusion
WAY-200070 stands out as a highly selective ERβ agonist with niche potential in metabolic, neurobehavioral, and endocrine research protocols — though it remains strictly a laboratory tool with no clinical adoption or routine community practice.
Key takeaways:
- Published dosing: 10–30 mg/kg once daily (subcutaneous or i.p.) in rodent models, with 10 mg/kg effective for β-cell and metabolic endpoints and 30 mg/kg for CNS/behavioral studies (Hughes 2008; Alonso-Magdalena 2013)
- Duration: functional action ≥24 hours; cycles in literature run 2–4 weeks
- Route: strictly parenteral in research (s.c., i.p.); compound is DMSO and oil soluble, poorly water soluble
- Stacking: co-administration with SERMs (e.g., tamoxifen) alters SERM response in vitro and should be treated as a flagged interaction (Lattrich 2014)
- No established role in physique or looksmaxxing stacks; theoretical use cases center on metabolic health, neuroprotection, and anti-proliferative ERβ signaling
- Safety margin and side-effect profile in higher species are uncharacterized; known hard contraindications include pregnancy, active thrombosis, and concurrent estrogenic agents
WAY-200070 excels as a research probe for selective ERβ activation but remains outside the scope of practical community use; any protocol must account for its uncharacterized safety and strictly preclinical profile.